EW Stock Price Edwards Lifesciences Corp Stock Quote U.S.: NYSE

There are currently 1 sell rating, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “hold” EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.

One share of EW stock can currently be purchased for approximately $81.58. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Out of 17 analysts, 6 (35.29%) are recommending EW as a Strong Buy, 4 (23.53%) are recommending EW as a Buy, 7 (41.18%) are recommending EW as a Hold, 0 (0%) are recommending EW as a Sell, and 0 (0%) are recommending EW as a Strong Sell. Ownerin %Freefloat98.85Vanguard Group, Inc. 8.05State Street Corp.4.49Capital Research & Management Co. 3.74AllianceBernstein LP3.60Vanguard Total Stock Market Index Fund3.11BlackRock Fund Advisors3.10Wellington Management Co.

At US$111, Is Edwards Lifesciences Corporation (NYSE:EW) Worth Looking At Closely?

Short interest in Edwards Lifesciences has recently increased by 6.77%, indicating that investor sentiment is decreasing significantly. 2.12% of the float of Edwards Lifesciences has been sold short. Please log in to your account or sign up in order to add this asset to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.

Provide specific products and services to you, such as portfolio management or data aggregation. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Represents the company’s profit divided by the outstanding shares of its common stock.

Intraday data delayed at least 15 minutes or per exchange requirements. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.

Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient’s heart function during surgery. The firm derives about 55% of its total sales from outside the U.S. On average, Wall Street analysts predict that Edwards Lifesciences’s share price could reach $93.80 by Mar 8, 2024.

Chairman & CEO exercised options and sold US$639k worth of stock

Approximately 2.1% of the shares of the stock are short sold. According to 15 Wall Street analysts that have issued a 1 year EW price target, the average EW price target is $93.80, with the highest EW stock price forecast at $138.00 and the lowest EW stock price forecast at $73.00. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023. Edwards Lifesciences has a short interest ratio (“days to cover”) of 3.2, which is generally considered an acceptable ratio of short interest to trading volume. In 2025, EW is forecast to generate $4,467,453,580,224 in revenue, with the lowest revenue forecast at $4,467,453,580,224 and the highest revenue forecast at $4,467,453,580,224. In 2025, EW is forecast to generate $2,019,600,475 in earnings, with the lowest earnings forecast at $2,019,600,475 and the highest earnings forecast at $2,019,600,475. Based on 17 analysts offering ratings for Edwards Lifesciences Corp.

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat’s FREE daily newsletter. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

Visit a quote page and your recently viewed tickers will be displayed here. Edwards Lifesciences has been rated by Canaccord Genuity Group, Morgan Stanley, Piper Sandler, Raymond James, Sanford how do stocks and the stock market work C. Bernstein, Truist Financial, and Wells Fargo & Company in the past 90 days. 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com.

Edwards Lifesciences downgraded to market perform at Raymond James on growth challenges

Sign Up NowGet this delivered to your inbox, and more info about our products and services. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.

Over the previous 90 days, Edwards Lifesciences’s stock had 4 downgrades by analysts. Edwards Lifesciences’ stock is owned by a number of institutional and retail investors. (3.60%), Moneta Group Investment Advisors LLC (2.49%), Brown Advisory Inc. (2.32%), Geode Capital Management LLC (1.96%), Norges Bank (1.43%) and Amundi (1.31%).

Financials

In the past three months, Edwards Lifesciences insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,902,704.00 in company stock. Edwards Lifesciences has received a 54.55% net impact score from Upright.

We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. The chart below shows how a company’s share price and consensus price target have changed over time. The lighter blue line represents the stock’s consensus price target.

Edwards Lifesciences stock price target raised to $113 from $84 at Deutsche Bank

The company issued revenue guidance of $5.60-$6.0 billion, compared to the consensus revenue estimate of $5.78 billion. Edwards Lifesciences’ stock was trading at $74.61 at the beginning of the year. Since then, EW shares have increased by 9.3% and is now trading at $81.58.

• Approximately 2.1% of the shares of the stock are short sold.
• The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy.
• Michael A. Mussallem has an approval rating of 90% among the company’s employees.
• Edwards Lifesciences’ stock is owned by a number of institutional and retail investors.

Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade. Edwards Lifesciences issued an update on its FY23 earnings guidance on Tuesday, January, 31st. The company provided earnings per share guidance of $2.45-$2.60 for the period, compared to the consensus earnings per share estimate of $2.50.

Edwards Sees Tepid TAVR Growth Thanks to Hospital Labor Issues

According to the issued ratings of 18 analysts in the last year, the consensus rating for Edwards Lifesciences stock is Hold based on the current 1 sell rating, 9 hold ratings and 8 buy ratings for EW. The average twelve-month price prediction for Edwards Lifesciences is $88.95 with a high price target of $134.00 and a low price target of $66.00. Edwards Lifesciences saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 12,770,000 shares, an increase of 6.8% from the February 13th total of 11,960,000 shares. Based on an average trading volume of 3,940,000 shares, the short-interest ratio is presently 3.2 days.

MarketBeat has tracked 11 news articles for Edwards Lifesciences this week, compared to 6 articles on an average week. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Edwards Lifesciences has received a consensus rating of Hold. The company’s average rating score is 2.39, and is based on 8 buy ratings, 9 hold ratings, and 1 sell rating. On average, 7 Wall Street analysts forecast EW’s revenue for 2024 to be $4,107,394,706,072, with the lowest EW revenue forecast https://day-trading.info/ at $4,022,229,005,692, and the highest EW revenue forecast at $4,193,104,238,628. On average, 7 Wall Street analysts forecast EW’s earnings for 2024 to be $1,867,522,126, with the lowest EW earnings forecast at $1,812,773,920, and the highest EW earnings forecast at $1,934,436,599.